DELFI Diagnostics Names Cindy Soriano CFO; Joins J.P. Morgan Healthcare Conference

DELFI Diagnostics Makes Key Leadership Change with Cindy Soriano as CFO

PALO ALTO, California, January 8, 2026 — DELFI Diagnostics, Inc., a company dedicated to advancing early cancer detection through blood-based liquid biopsy tests, has announced the appointment of Cindy Soriano as their new Chief Financial Officer (CFO). As the company gears up to achieve significant clinical and regulatory milestones, Soriano’s leadership is expected to be pivotal.

Strategic Appointment of Cindy Soriano

Cindy Soriano’s promotion to CFO comes at an essential juncture for DELFI, where the focus is not just on innovation but also on establishing a solid financial foundation. After serving as Vice President of Finance and Investor Relations for over three years, Soriano has played an essential role in the company’s two successful fundraising rounds.

Susan Tousi, the CEO of DELFI Diagnostics, expressed confidence in Soriano’s abilities: “Cindy’s strategic vision, operational rigor, and collaborative approach will be essential as we work to deliver on our mission and create long-term value.” Her extensive background includes over 20 years of finance leadership, mainly within the life sciences sector, which positions her well to guide DELFI through its next stages of growth.

Prior to her role at DELFI, Soriano held prominent finance positions at companies like Zogenix and BioMarin Pharmaceuticals, leading financial organizations through key phases of both growth and integration post-acquisition. Her rich experience in operational and strategic planning will be vital as DELFI aims to introduce significant products addressing pressing healthcare needs.

Upcoming Presentation at the J.P. Morgan Healthcare Conference

To further bolster its visibility within the healthcare sector, DELFI Diagnostics will have CEO Susan Tousi present at the esteemed 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco. On January 15, 2026, at 9:30 a.m. PT, Tousi will share insights about DELFI's progress, focusing on current and future strategic priorities. The conference is known for being a premier platform for healthcare companies to engage with investors and stakeholders.

During her presentation, Tousi is expected to discuss the company’s revolutionary approach to cancer diagnostics through liquid biopsy tests. DELFI’s signature test, FirstLook Lung, is engineered to detect lung cancer through a simple blood draw—integrating seamlessly with routine healthcare procedures.

About DELFI Diagnostics

DELFI Diagnostics is pioneering next-generation tests that are designed to enhance cancer detection using easily accessible blood samples. Their innovative testing technology aims to fundamentally transform patient outcomes across various demographics, particularly in communities that have historically lacked access to advanced cancer detection methods.

The FirstLook Lung test utilizes cutting-edge techniques, analyzing cell-free DNA (cfDNA) fragments in the blood. The technology is based on the premise that cancer cells behave differently from normal cells, leading to identifiable patterns in the blood that can indicate cancer presence. With a stellar negative predictive value of 99.8 percent, this test represents a significant step forward in early cancer detection methods.

As DELFI prepares for its presentation and continues to build its strategic and operational framework under Soriano’s leadership, the company remains committed to its mission of leveraging technological advancements in genomics to save lives globally.

For anyone interested in learning more about DELFI Diagnostics and its innovative cancer detection technologies, visit DELFIDIagnostics.com.

Conclusion

The strategic appointment of Cindy Soriano marks a new chapter in DELFI Diagnostics’ journey, aimed at impactful innovations in the healthcare space. With upcoming presentations at high-profile events like the J.P. Morgan Healthcare Conference, DELFI looks poised for continued success in its mission to redefine cancer detection.